SecBot SecBot
8-K ·Filed May 12, 2026

PEPG

PepGen Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed6mo ago SEC0001193125-26-219424
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The stock will trade on FREEDOM2 10 mg/kg data in 2H 2026 and resolution of the FDA partial clinical hold. Near-term catalyst is limited, monitor for FDA feedback and any preclinical study updates. The improved cash position reduces near-term dilution risk.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.78
T+0 close · May 12, 2026 · via day close
Latest settled
+60.11%
T+60 · $2.85
Vs SPY
+55.67%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $1.78entry
  2. T+1 · 6mo ago 0.00%α +0.00% · $1.78
  3. T+5 · 6mo ago −22.47%α −21.31% · $1.38
  4. T+20 · 5mo ago −15.17%α −14.56% · $1.51
  5. T+60 · 3mo ago +60.11%α +55.67% · $2.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PepGen reported Q1 2026 net loss of $17.8M ($-0.26/share), narrower than the $30.2M loss in Q1 2025, with cash of $132.3M sufficient into 2H 2027. The FREEDOM2-DM1 5 mg/kg cohort showed favorable safety and efficacy data, the 10 mg/kg cohort is fully enrolled with data expected in 2H 2026, but an FDA partial clinical hold remains unresolved.

Key Financial Metrics

EPS
−$0.26
est −$0.31 · +16.1%

Key Facts

  • Net loss of $17.8M ($-0.26/share) for Q1 2026 vs $30.2M ($-0.92/share) in Q1 2025
  • Cash, cash equivalents and marketable securities of $132.3M as of March 31, 2026
  • FREEDOM2-DM1 5 mg/kg cohort demonstrated favorable safety, splicing and vHOT data
  • FREEDOM2 10 mg/kg cohort fully enrolled, data on track for 2H 2026
  • FDA partial clinical hold on FREEDOM2 study remains unresolved
  • 13 patients enrolled in open label extension at 5 mg/kg with no discontinuations

Financial Impact

Net loss improved by $12.4M YoY to $17.8M; cash burn of $16.2M in Q1 2026

net losscash positionR&D expenses

Risk Factors

  • FDA partial clinical hold could delay or derail FREEDOM2 trial if not resolved
  • 10 mg/kg cohort data may not replicate 5 mg/kg safety/efficacy profile
  • Pre-revenue biotech with no approved products, binary clinical risk
  • Cash runway only into 2H 2027, potential future dilution

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-219424
Document: pepg-20260512.htm0001193125-26-219424
Document: 0001193125-26-219424-index-headers.html0001193125-26-219424
Document: 0001193125-26-219424-index.html0001193125-26-219424
Document: 0001193125-26-219424.txt0001193125-26-219424
8-K Data (Synthetic)0001193125-26-219424

Track record

12 reports on PEPG

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +31.95% at T+20 after the Aug 6, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Entry $4.36 to $4.19 Now $4.19 +3.90% ▲ +3.90% +1.99% vs SPY
  2. Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $4.36 to $4.19 Now $4.19 +3.90% ▲ +3.90% +1.99% vs SPY
  3. Nov 10, 20266d ago 424B5 Bearish 6/10 Entry $5.26 to $5.04 Now $4.19 +20.34% ▲ +4.18% +3.83% vs SPY
  4. Nov 10, 20266d ago 8-K Bullish 7/10 Entry $4.61 to $5.26 Now $4.19 −9.11% ▲ +14.10% +12.78% vs SPY
  5. Aug 6, 202614w ago 8-K Bullish 7/10 Entry $2.41 to $2.85 Now $4.19 +73.86% ▲ +18.26% +17.65% vs SPY
  6. Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.51 to $1.47 Now $4.19 +177.48% ▼ −2.65% −3.19% vs SPY
  7. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $1.51 to $1.47 Now $4.19 +177.48% ▼ −2.65% −3.19% vs SPY
  8. May 22, 202625w ago EFFECT Bearish 7/10 Entry $1.51 to $1.53 Now $4.19 −177.48% ▼ −1.32% −0.74% vs SPY
  9. May 19, 202625w ago S-3 Bearish 7/10 Entry $1.38 to $1.44 Now $4.19 −203.62% ▼ −4.35% −3.31% vs SPY
  10. May 12, 202626w ago 8-K Neutral 5/10 Viewing Entry $1.78 to $1.78 Now $4.19 +135.39% · 0.00% +0.00% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026